Isoflurane

Isoflurane, USP liquid for inhalation may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. Isoflurane, USP liquid for inhalation, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia. (1)

12. CLINICAL PHARMACOLOGY 12.2 Pharmacodynamics Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency which limits the rate of induction, although excessive salivation or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily obtunded. The level of anesthesia may be changed rapidly with isoflurane. Isoflurane is a profound respiratory depressant. As anesthetic dose is increased, tidal volume decreases and respiratory rate is unchanged. This depression is partially reversed by surgical stimulation, even at deeper levels of anesthesia.

Clinical clearance of Isoflurane (General Anesthetic) relies on systemic clearance of isoflurane integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 8 to 19 hours per Isoflurane clinical pharmacology half-life; patients absorbing at Consistent 55%–67% gastrointestinal absorption profile for Isoflurane bioavailability typically observe target onset around cmax attained 2–5 hours post-administration of isoflurane.

FDA clinical labeling for Isoflurane restricts administration in contraindications isoflurane, usp liquid for inhalation is contraindicated in patients: in whom general anesthesia is contraindicated.; with known sensitivity to isoflurane, usp liquid for inhalation or to other halogenated agents .; with known or suspected genetic susceptibility to malignant hyperthermia . across 100 mL/100mL Liquid, 250 mL/250mL Liquid, 1 mL/mL Liquid, 1 mL/mL Inhalant, with self-reported patient tracking dominated by nausea (11.3% of reports), headache (8.5% of reports), dizziness (5.8% of reports).